This event has passed.
CANCELLED – Biomarkers Symposium
March 31, 2020 @ 8:00 am - 4:00 pm
This event has been cancelled.
Registration
Introduction
Novel Approaches to cfDNA Biomarkers that Do Not Require Sequencing for Mutations
Nic Dracopoli, Ph.D. (Chief Scientific Officer, Delfi Diagnostics)
Insights into Association of Cancer Cachexia and Catabolic Clearance with Response Gained from Pembrolizumab Exposure-Response Assessments
Julie Stone, Ph.D. (Scientific AVP, Dept. of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc.)
Challenges and Strategies in LC-MS/MS Bioanalysis of PD-1 and PD-L1 as Clinical Biomarkers in Formalin Fixed Paraffin Embedded (FFPE) Tissues for Cancer Immunotherapy Development
Naiyu Zheng, Ph.D. (Senior Principal Scientist, Department of Translational Medicine, Bristol-Myers Squibb Company, Princeton, NJ)
Amantadine as a Biomarker Drug for Detection and Therapeutic Monitoring of Cancer
Donald Miller, Ph.D. (Professor, Department of Pharmacology & Therapeutics, Kleysen Institute for Advanced Medicine, University of Manitoba)
Metabolomics, Biomarkers, and Cancer
David Wishart, Ph.D. (Professor, Departments of Biological Sciences and Computing Science, University of Alberta)
The Role for Comprehensive Genomic Profiling in Clinical Studies
Tim Burn, Ph.D. (VP, Translational Research, Incyte Corporation)
Reevaluation of Using the Mental and Physical Test Scores to Determine the Extent of Mercury Toxicity – Monitoring Test Scores Using the Chelation Agent N,N’-Bis-(2-mercaptoethyl) Isophthalamide
Chris Kemper, Ph.D. (PK/PD/Bioanalytical Consulting, Pharma Navigators, LLC)